Level of vitamin D binding protein of cerebrospinal fluid in meningitis and its effect on clinical treatment

doi:10.3877/cma.j.issn.2095-123X.2019.06.010

Abstract

Abstract:

Objective

To investigate the expression of vitamin D binding protein (VDBP) in meningitis and its effect on the therapeutic effect.

Methods

One hundred and seven cases of meningitis patients from June 2016 to June 2019 were selected as the research object, including 26 cases of viral meningitis, 63 cases of bacterial meningitis, 18 cases of tuberculous meningitis, then detect the cerebrospinal fluid VDBP level of all patients, and then patients were divided into VDBP high level and VDBP low level group according to the VDBP expression level, patients with high level and low level group on the sensitivity of the treatment, the curative effect of clinical treatment and clinical prognosis.

Results

The average level of VDBP in CSF of patients with bacterial meningitis [(3.23±0.98)μg/mL] was lower than that in viral meningitis [(3.87±1.19)μg/mL] and tuberculous meningitis[(4.02±1.40)μg/mL], the difference was statistically significant (P<0.05). The average onset time of high VDBP group was (4.82±1.46)d longer than that of low VDBP group (3.75±1.19)d, the mean rank of clinical efficacy was (60.33) lower than that of low VDBP group (88.50), the incidence of adverse events (64.29%) and the complication rate (57.14%) higher than that of low VDBP group (24.14%, 24.14%), the difference was statistically significant (P<0.05).

Conclusion

The higher the content of cerebrospinal fluid VDBP in patients with meningitis, the longer the duration of treatment, the worse the curative effect, and the higher the probability of adverse events and complications, which can be used as a reference index to guide clinical treatment and adverse events prevention.

Key words: Meningitis, Vitamin D binding protein, Adverse events

Zhimin Liu, Yi Wu, Zai Liang. Level of vitamin D binding protein of cerebrospinal fluid in meningitis and its effect on clinical treatment[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2019, 09(06): 364-367.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2019.06.010

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2019/V09/I06/364

Figures/Tables 2

References 17

[1]	Chun RF. New perspectives on the vitamin D binding protein[J]. Cell Biochem Funct, 2012, 30(6): 445-456.
[2]	杨骏杰,张岩,李晨光,等.维生素D结合蛋白及其基因多态性的研究进展[J].上海医学, 2019, 42(5): 308-313.
[3]	Heijboer AC, Blankenstein MA, Kema IP, et al. Accuracy of 6 routine 25-hydroxyvitamin D assays: Influence of vitamin D binding protein concentration[J]. Clin Chem, 2012, 58(3): 543-548.
[4]	Schwartz JB, Lai J, Lizaola B, et al. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations[J]. J Clin Endocrinol Metab, 2014, 99(5): 1631-1637.
[5]	冯娟,夏维波.脑脊液维生素D结合蛋白研究进展[J].国际内分泌代谢杂志, 2016, 36(3): 209-213.
[6]	Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein[J]. Trends Biotechnol, 2004, 22(7): 340-345.
[7]	Lee DH, Kang H, Kim JH, et al. Cerebrospinal fluid vitamin D-binding protein as a new biomarker for the diagnosis of meningitis[J]. Neurol Sci, 2019, 40(8): 1597-1605.
[8]	童辉,徐胜前,龚勋,等.维生素D结合蛋白在类风湿关节炎中的研究进展[J].中华风湿病学杂志, 2017, 21(11): 777-779.
[9]	Martinez-Bravo MJ, Wahlund CJ, Qazi KR, et al. Pulmonary sarcoidosis is associated with exosomal vitamin D-binding protein and inflammatory molecules[J]. J Allergy Clin Immunol, 2017, 139(4): 1186-1194.
[10]	White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein[J]. Trends Endocrinol Metab, 2000, 11(8): 320-327.
[11]	欧伟杰,林烨鸿,周卿,等.维生素D相关基因单核苷酸多态性与HBV相关慢加急性肝衰竭的相关性分析[J].临床肝胆病杂志, 2019, 35(6): 1308-1312.
[12]	何国华,容丽萍,姜梦婕,等. IgA肾病大鼠尿维生素D结合蛋白与肾脏纤维化关系的研究[J].中国现代医学杂志, 2018, 28(24): 1-5.
[13]	Song DK, Lee H, Hong YS, et al. Vitamin D receptor and binding protein polymorphisms in women with polycystic ovary syndrome: a case control study[J]. BMC Endocr Disord, 2019, 19(1): 145.
[14]	Dimova R, Chakarova N, Kirilov G, et al. Vitamin D binding protein is related to cardiac autonomic function and metabolic status in prediabetes[J]. Nutr Res, 2020, 75: 56-66.
[15]	Navarrete-Dechent C, Del Puerto C, Molgo M, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study[J]. J Am Acad Dermatol, 2017, 77(3): 575-577.
[16]	Yang M, Qin Z, Zhu Y, et al. Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression[J]. Mol Neurobiol, 2013, 47(3): 946-956.
[17]	Jeon SG, Cha MY, Kim JI, et al. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer’s disease-related pathology in 5XFAD mice[J]. Nanomedicine, 2019, 17: 297-307.

项目		病毒性脑膜炎（n=26）	细菌性脑膜炎（n=63）	结核性脑膜炎（n=18）
性别比例（男/女）		16/10	37/26	12/6
年龄分布		?	?	?
?	<1岁	1	5	0
?	1~17岁	18	39	4
?	18~60岁	7	17	13
?	>60岁	0	2	1
平均年龄（岁）		13.50±10.62	15.63±13.80	29.56±16.88

项目		病毒性脑膜炎（n=26）	细菌性脑膜炎（n=63）	结核性脑膜炎（n=18）
性别比例（男/女）		16/10	37/26	12/6
年龄分布		?	?	?
?	<1岁	1	5	0
?	1~17岁	18	39	4
?	18~60岁	7	17	13
?	>60岁	0	2	1
平均年龄（岁）		13.50±10.62	15.63±13.80	29.56±16.88

项目		VDBP高水平组（n=28）	VDBP低水平组（n=29）	t/χ²值	P值
起效时间（Mean±SD，d）		4.82±1.46	3.75±1.19	3.042	0.002
?	病毒性脑膜炎	4.48±1.16	3.19±0.96	2.290	0.041
?	细菌性脑膜炎	4.50±1.15	3.65±1.06	2.280	0.029
?	结核性脑膜炎	7.13±1.25	5.25±0.87	2.466	0.049
临床疗效（平均秩）		60.33	88.50	4.504	<0.001
?	病毒性脑膜炎	13.71	22.22	2.483	0.013
?	细菌性脑膜炎	39.82	55.36	3.298	0.001
?	结核性脑膜炎	7.44	11.86	1.997	0.046
不良事件[例（%）]		18（64.29）	7（24.14）	9.325	0.002
?	病毒性脑膜炎	4（66.67）	1（12.50）	?	?
?	细菌性脑膜炎	12（66.67）	5（29.41）	?	?
?	结核性脑膜炎	2（50.00）	1（25.00）	?	?
并发症[例（%）]		16（57.14）	7（24.14）	6.447	0.011
?	病毒性脑膜炎	5（83.33）	2（25.00）	?	?
?	细菌性脑膜炎	9（50.00）	3（17.65）	?	?
?	结核性脑膜炎	1（25.00）	2（50.00）	?	?

项目		VDBP高水平组（n=28）	VDBP低水平组（n=29）	t/χ²值	P值
起效时间（Mean±SD，d）		4.82±1.46	3.75±1.19	3.042	0.002
?	病毒性脑膜炎	4.48±1.16	3.19±0.96	2.290	0.041
?	细菌性脑膜炎	4.50±1.15	3.65±1.06	2.280	0.029
?	结核性脑膜炎	7.13±1.25	5.25±0.87	2.466	0.049
临床疗效（平均秩）		60.33	88.50	4.504	<0.001
?	病毒性脑膜炎	13.71	22.22	2.483	0.013
?	细菌性脑膜炎	39.82	55.36	3.298	0.001
?	结核性脑膜炎	7.44	11.86	1.997	0.046
不良事件[例（%）]		18（64.29）	7（24.14）	9.325	0.002
?	病毒性脑膜炎	4（66.67）	1（12.50）	?	?
?	细菌性脑膜炎	12（66.67）	5（29.41）	?	?
?	结核性脑膜炎	2（50.00）	1（25.00）	?	?
并发症[例（%）]		16（57.14）	7（24.14）	6.447	0.011
?	病毒性脑膜炎	5（83.33）	2（25.00）	?	?
?	细菌性脑膜炎	9（50.00）	3（17.65）	?	?
?	结核性脑膜炎	1（25.00）	2（50.00）	?	?

Please choose a citation manager

Content to export